Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

Inclusion Criteria

• •For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
• •Ovarian cancer that is not refractory or resistant to platinum-based therapy (refactory=progression while receiving any previous platinum regimen; resistant=progression within 6 months of any previous platinum regimen)
• •Recipients of platinum/taxane-based chemotherapy as frontline regimen for ovarian cancer
• •An Eastern Cooperative Oncology Group performance status ≤1
• •Up to 4 prior lines of therapy for ovarian cancer
• •Two groups are eligible:
• •Group 1. Women who have not met the criteria for progressive disease following their most recent chemotherapeutic regimen were required to have:
• •Demonstrated partial response or stable disease following the most recent chemotherapy regimen
• •Evaluable or measurable disease, detected by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan
• •Received the last dose of their most recent chemotherapeutic regimen for ovarian cancer within 4 to 12 weeks of the first administration of ipilimumab Group 2: Women with disease progression while receiving or following the last dose of the most recent chemotherapeutic regimen were required to have:
• •Measurable disease on a CT or MRI scan performed within 28 days of first dose of ipilimumab.
• •Received the last dose of their most recent chemotherapeutic regimen for ovarian cancer at least 4 weeks prior to the first administration of ipilimumab.